RxDoctor Payments Data

James Gullett, MD

Ophthalmology · Georgetown, KYNPI 1073748158

Payments from drug & device makers

$2,490in general payments, 2019–2025

Across 107 payments — averaging $23.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson Vision Care, Inc.$630
  • Alcon$412
  • Mallinckrodt Hospital Products Inc.$223
  • Rayner Intraocular Lenses Limited$198
  • Novartis$193
  • AbbVie$173
  • plus $659 from 9 others

What the payments were for

  • Food & beverage$2,26391%
  • Education$2279%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,490 in reported general payments places this provider in the 60th percentile of 216 ophthalmology providers in Kentucky.

See all ophthalmology providers in Kentucky

Medicare billing

Part B allowed, 2024
$152,875
Medicare patients
382
Services billed
971

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine20$25,292
XiidraLifitegrast11$18,548
Cyclosporine13$9,991
Prednisolone Acetate339$8,404
MoxifloxacinMoxifloxacin Hcl252$7,518
RocklatanNetarsudil Mesylat/Latanoprost22$7,273
LumiganBimatoprost17$6,357
CombiganBrimonidine Tartrate/Timolol20$4,692
Ketorolac Tromethamine307$4,614
Latanoprost188$1,972
Timolol Maleate93$1,127
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat45$906
Doxycycline Monohydrate19$499
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha33$350
ErythromycinErythromycin Base35$347

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$173$36,34157 claims
Bausch & Lomb Americas Inc.Xiidra$121$18,54811 claims
Aerie Pharmaceuticals, Inc.Rocklatan$90$7,27322 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 216 ophthalmology providers in Kentucky.

Other ophthalmology in Georgetown

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →